The Abortion Trap: How America's obsession with abortion hurts families everywhere
By Mara Hvistendahl,
Foreign Policy
| 07. 26. 2011
[Quotes CGS's Marcy Darnovsky]
For nearly two decades, anti-abortion activists have been at work in a disingenuous game, using the stark reduction of women in the developing world as an argument for taking away hard-earned rights. Conservative theorists have written openly about how sex-selective abortion is merely a convenient wedge issue in the drive to ban all abortions, both in the United States and abroad. And now, conservative commentators like the New York Times' Ross Douthat, the Wall Street Journal's Jonathan V. Last, and the editors of the New York Sun have claimed that my book, Unnatural Selection, strengthens their case.
This does not surprise me. One of the themes that cropped up again and again in my reporting was the extent to which American abortion politics on both sides of the question has stalled action on issues of major global importance. But it is deeply unfortunate. The American obsession with abortion does not just hinder work on maternal and child health or access to safe birth control abroad -- two areas that have suffered because of domestic campaigns by anti-abortion activists. It's also...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...